BioXcel Therapeutics, Inc.
BTAI
$1.31
$0.064.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -74.95% | -15.53% | -126.45% | -131.20% | 72.92% |
| Total Depreciation and Amortization | -23.68% | -3.90% | -2.60% | -2.60% | -2.56% |
| Total Amortization of Deferred Charges | 43.43% | 111.26% | 315.09% | 309.38% | 713.95% |
| Total Other Non-Cash Items | 71.70% | 6.67% | 953.04% | 138.84% | -177.38% |
| Change in Net Operating Assets | 185.28% | 46.69% | -20.63% | 144.36% | -137.07% |
| Cash from Operations | 1.94% | 4.04% | -14.99% | 45.74% | 31.98% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -39.33% | -17.70% | 8,069.66% | -97.44% | -47.63% |
| Repurchase of Common Stock | -- | 100.00% | -- | 100.00% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 80.32% | 35.75% | -4,800.00% | 98.17% | -586.32% |
| Cash from Financing | -98.24% | 32.06% | 8,166.96% | -97.42% | -50.42% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1,098.88% | 18.70% | 218.01% | 30.40% | -87.01% |